Ace inhibitor effect on kidney
Pro Research Analysisby 
Searched over 200M research papers
ACE Inhibitors and Their Effects on Kidney Health
Introduction to ACE Inhibitors and Kidney Health
Angiotensin-converting enzyme (ACE) inhibitors are a class of medications widely used to manage hypertension and chronic kidney disease (CKD). They work by inhibiting the renin-angiotensin system (RAS), which plays a crucial role in blood pressure regulation and kidney function. This article synthesizes research findings on the effects of ACE inhibitors on kidney health, particularly in patients with CKD.
ACE Inhibitors and Kidney Failure Prevention
Reduction in Kidney Failure Risk
Multiple studies have demonstrated that ACE inhibitors significantly reduce the risk of kidney failure in patients with CKD. A comprehensive Bayesian network meta-analysis of 119 randomized controlled trials involving 64,768 patients found that ACE inhibitors reduced the odds of kidney failure by 39% compared to placebo and by 35% compared to other active controls . Another meta-analysis of 44 randomized clinical trials with 42,319 patients confirmed that ACE inhibitors significantly decreased the odds of kidney events (OR 0.54, 95% CI 0.41–0.73) compared to placebo .
Efficacy in Diabetic and Nondiabetic Renal Disease
ACE inhibitors are effective in both diabetic and nondiabetic renal disease. In patients with diabetic nephropathy, ACE inhibitors delay the progression from microalbuminuria to macroalbuminuria and reduce the risk of end-stage renal disease (ESRD) . Similarly, in nondiabetic renal disease, ACE inhibitors have been shown to slow the progression of renal dysfunction and reduce proteinuria, a key marker of kidney damage 45.
Cardiovascular Benefits of ACE Inhibitors
Reduction in Cardiovascular Events
ACE inhibitors not only protect kidney function but also offer cardiovascular benefits. They have been shown to reduce the odds of major cardiovascular events by 18% compared to placebo . In patients with CKD stages 3-5, ACE inhibitors significantly decreased the odds of cardiovascular events (OR 0.73, 95% CI 0.64–0.84) and cardiovascular death (OR 0.73, 95% CI 0.63–0.86) .
Comparison with ARBs
While both ACE inhibitors and angiotensin II receptor blockers (ARBs) are effective in reducing cardiovascular events, ACE inhibitors may offer superior benefits. Studies have consistently shown that ACE inhibitors are more effective than ARBs in reducing the risk of all-cause mortality and kidney failure 12.
Safety and Adverse Effects
Hyperkalemia and Cough
The use of ACE inhibitors is associated with certain adverse effects, including hyperkalemia and cough. ACE inhibitors have been shown to increase the odds of hyperkalemia significantly compared to other antihypertensive drugs 29. Additionally, patients on ACE inhibitors are more likely to experience cough compared to those on placebo or other antihypertensive medications .
Monitoring and Management
Despite these adverse effects, the benefits of ACE inhibitors in preventing kidney failure and cardiovascular events outweigh the risks. Careful monitoring of renal function and serum potassium levels is essential to mitigate these risks. Adjustments in dosage and co-treatment with diuretics can help manage hyperkalemia and improve therapeutic outcomes 89.
Conclusion
ACE inhibitors play a crucial role in managing CKD by reducing the risk of kidney failure and cardiovascular events. They are effective in both diabetic and nondiabetic renal disease and offer superior benefits compared to ARBs. While associated with some adverse effects, careful monitoring and management can help mitigate these risks, making ACE inhibitors a valuable treatment option for patients with CKD.
Sources and full results
Most relevant research papers on this topic